Trending NewsTrending NewsNASDAQ:VALN Valneva (VALN) Stock Price, News & Analysis $8.96 -0.47 (-4.98%) Closing price 04:00 PM EasternExtended Trading$9.02 +0.06 (+0.67%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Valneva Stock (NASDAQ:VALN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Valneva alerts:Sign Up Key Stats Today's Range$8.80▼$9.1850-Day Range$5.56▼$12.1452-Week Range$3.62▼$12.25Volume1.01 million shsAverage Volume71,196 shsMarket Capitalization$762.44 millionP/E RatioN/ADividend YieldN/APrice Target$15.33Consensus RatingBuy Company Overview Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. Read More Valneva Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreVALN MarketRank™: Valneva scored higher than 42% of companies evaluated by MarketBeat, and ranked 650th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingValneva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageValneva has only been the subject of 2 research reports in the past 90 days.Read more about Valneva's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Valneva are expected to decrease in the coming year, from $0.13 to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Valneva is -9.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Valneva is -9.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioValneva has a P/B Ratio of 3.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Valneva's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.05% of the float of Valneva has been sold short.Short Interest Ratio / Days to CoverValneva has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Valneva has recently increased by 91.18%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldValneva does not currently pay a dividend.Dividend GrowthValneva does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.05% of the float of Valneva has been sold short.Short Interest Ratio / Days to CoverValneva has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Valneva has recently increased by 91.18%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.30 News SentimentValneva has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 31 news articles for Valneva this week, compared to 5 articles on an average week.Search Interest4 people have searched for VALN on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Valneva insiders have not sold or bought any company stock.Percentage Held by Insiders14.91% of the stock of Valneva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.39% of the stock of Valneva is held by institutions.Read more about Valneva's insider trading history. Receive VALN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VALN Stock News HeadlinesValneva Outlook: Safety Blow To Ixchiq And Valuation ConcernsAugust 26 at 7:30 AM | seekingalpha.comValneva Stock Tumbles 19% After FDA Suspension Of Ixchiq License In US, Wall Street Divided On The ImpactAugust 26 at 5:16 AM | msn.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.August 26 at 2:00 AM | American Alternative (Ad)Valneva stock tumbles as FDA suspends license for IXCHIQ vaccineAugust 25 at 2:13 PM | za.investing.comValneva Shares Tumble After Chikungunya Vaccine License Suspended in U.S.August 25 at 2:13 PM | marketwatch.comSafety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In USAugust 25 at 2:13 PM | benzinga.comValneva shares tumble after suspension of US chikungunya vaccine licenceAugust 25 at 2:13 PM | msn.comKeurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On MondayAugust 25 at 12:02 PM | benzinga.comSee More Headlines VALN Stock Analysis - Frequently Asked Questions How have VALN shares performed this year? Valneva's stock was trading at $4.37 on January 1st, 2025. Since then, VALN shares have increased by 105.0% and is now trading at $8.96. How were Valneva's earnings last quarter? Valneva SE Sponsored ADR (NASDAQ:VALN) posted its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.11. The company earned $54.84 million during the quarter, compared to analyst estimates of $46.28 million. Valneva had a negative trailing twelve-month return on equity of 34.78% and a negative net margin of 33.87%. Read the conference call transcript. When did Valneva IPO? Valneva (VALN) raised $99 million in an IPO on Thursday, May 6th 2021. The company issued 3,500,000 shares at a price of $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. served as the underwriters for the IPO. Who are Valneva's major shareholders? Valneva's top institutional shareholders include Frazier Life Sciences Management L.P. (1.71%) and Marex Group plc (0.01%). How do I buy shares of Valneva? Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Valneva own? Based on aggregate information from My MarketBeat watchlists, some other companies that Valneva investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/12/2025Today8/26/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VALN CIK1836564 Webvalneva.com Phone33-2-28-07-37-10FaxN/AEmployees700Year FoundedN/APrice Target and Rating Average Price Target for Valneva$15.33 High Price Target$18.00 Low Price Target$14.00 Potential Upside/Downside+71.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.98) Trailing P/E RatioN/A Forward P/E Ratio68.92 P/E GrowthN/ANet Income-$13.25 million Net Margins-33.87% Pretax Margin-6.77% Return on Equity-34.78% Return on Assets-13.43% Debt Debt-to-Equity Ratio0.66 Current Ratio2.27 Quick Ratio1.77 Sales & Book Value Annual Sales$196.33 million Price / Sales3.88 Cash Flow$0.08 per share Price / Cash Flow119.13 Book Value$2.41 per share Price / Book3.72Miscellaneous Outstanding Shares85,094,000Free Float72,406,000Market Cap$762.44 million OptionableNot Optionable Beta1.77 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:VALN) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBREAKING: Meta, Apple and NASA rush to invest in new "E.I." techBig Tech and even NASA are racing to back a breakthrough known as “E.I. Tech,” set to launch September 1st. Ex...Behind the Markets | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.